NCT06619054View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

June 4, 2025

Study Completion Date

July 4, 2025

Conditions
Healthy AdultsHepatic Impairment
Interventions
DRUG

KP-001

Oral single dose 50mg.

Sponsors
All Listed Sponsors
lead

Kaken Pharmaceutical

INDUSTRY